Intervention

PSMA PET Scan

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 18 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials18

Recruiting10

Common conditions25

Lead sponsors shown12

Clinical trials

18 shown

Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO TrialNCT07698535 · 2026-10-01

Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate CancerNCT07468903 · 2026-05-11

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL TrialNCT07200830 · 2026-03-31

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate CancerNCT07219147 · 2026-03-06

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE TrialNCT06931340 · 2025-12-01

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialNCT06632977 · 2025-02-06

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)NCT06216249 · 2024-08-01

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene MutationNCT05806515 · 2024-03-01

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate CancerNCT05438563 · 2022-04-06

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC StudyNCT04175431 · 2020-09-30

Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate CancerNCT07860554 · 2026-11-02

NOT_YET_RECRUITING

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to BonesNCT06982222 · 2026-10-01

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP StudyNCT05960578 · 2024-05-23

ACTIVE_NOT_RECRUITING

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate CancerNCT06129851 · 2023-11-20

NOT_YET_RECRUITING

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate CancerNCT05733351 · 2023-08-03

MRI Guided Radiation Therapy for the Treatment of High Risk Prostate CancerNCT05676463 · 2022-11-16

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean StudyNCT05053152 · 2022-04-20

ACTIVE_NOT_RECRUITING

Comparison of PET Imaging Patterns With PSMA and AR Expression in Prostate Cancer and Bladder CancerNCT05109884 · 2020-02-01

Common conditions

Stage IVB Prostate Cancer AJCC v89 Prostate Adenocarcinoma6 Metastatic Prostate Adenocarcinoma4 Metastatic Castration-Resistant Prostate Adenocarcinoma3 Castration-Sensitive Prostate Carcinoma2 Metastatic Castration-Resistant Prostate Carcinoma2 Prostate Carcinoma2 Stage II Prostate Cancer AJCC v82 Stage IIIB Prostate Cancer AJCC v82 Stage IIIC Prostate Cancer AJCC v82 Stage IV Prostate Cancer AJCC v82 Anatomic Stage IV Breast Cancer AJCC v81 Castration-Resistant Prostate Carcinoma1 Metastatic Breast Carcinoma1 Metastatic Lung Non-Small Cell Carcinoma1 Metastatic Malignant Neoplasm in the Bone1 Oligometastatic Prostate Carcinoma1 Prostate Cancer1 Prostate Ductal Adenocarcinoma1 Prostate Intraductal Carcinoma1 Stage I Prostate Cancer AJCC v81 Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v81 Stage IIC Prostate Cancer AJCC v81 Stage III Prostate Cancer AJCC v81 Stage IV Lung Cancer AJCC v81

Leading sponsors

Alliance for Clinical Trials in Oncology 3 University of Washington 3 Emory University 2 Jonsson Comprehensive Cancer Center 2 City of Hope Medical Center 1 Mayo Clinic 1 Medical University of Vienna 1 National Cancer Institute (NCI) 1 NRG Oncology 1 SWOG Cancer Research Network 1 Thomas Jefferson University 1 University of Kansas Medical Center 1

Trial status mix

RECRUITING10

ACTIVE_NOT_RECRUITING2

NOT_YET_RECRUITING2

TERMINATED2

COMPLETED1

WITHDRAWN1

Phase mix

PHASE210

NA3

PHASE13

PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.